Ezetimibe/pitavastatin - JW Pharmaceutical
Alternative Names: Ezetimibe/pitavastatin calcium - JW Pharmaceutical; LIVALO-Z; LivaloZet; Pitavastatin 2mg/ezetimibe 10mg - JW Pharmaceutical; Pitavastatin 4mg/ezetimibe 10mg - JW Pharmaceutical; Pitavastatin calcium/ezetimibe - JW Pharmaceutical; Pitavastatin/ezetimibe - JW PharmaceuticalLatest Information Update: 09 Aug 2023
At a glance
- Originator JW Pharmaceutical
- Class Antihyperlipidaemics; Azetidines; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Phenols; Propanols; Quinolines; Small molecules
- Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia
Most Recent Events
- 09 Aug 2023 Chemical structure information added
- 18 Jul 2023 Launched for Hyperlipidaemia in South Korea (PO, Tablet 10mg/2mg) prior to July 2023 (JW Pharmaceutical website, July 2023)
- 18 Jul 2023 Launched for Hyperlipidaemia in South Korea (PO, Tablet 10mg/4mg) prior to July 2023 (JW Pharmaceutical website, July 2023)